
D
Tier
Elongated octapeptide successor to Argireline for expression lines.
Skin & Beauty
Peptide, 8 amino acids
WADA Status:
Not listed
Human Trial Scoreboard
Completed human RCTs
Count not verified
Largest Human Study
Size not verified
Longest exposure
Duration not verified
Most Recent Trial
Year not verified
Description
SNAP-8, or acetyl octapeptide-3, is an eight amino acid cosmetic peptide developed as an extended version of argireline, with two additional amino acids intended to improve its activity. It is proposed to work the same way, by interfering with the signalling that triggers muscle contraction in the skin, and it carries the same topical Botox framing and the same problem with it. The evidence is limited to cosmetic testing rather than controlled clinical trials, and the effect is modest. It sits in the legitimate but oversold category: a genuine cosmetic ingredient whose marketing invites a comparison it cannot support.
What Are The Claims
Claims made for this compound: Targets the SNAP-25 mechanism to soften expression lines; Marketed as deeper-acting than Argireline; Topical and non-invasive
Evidence
Marketed as an extension of Argireline's mechanism, with a thinner published base than Argireline itself.
Evidence Strength
Traditional/anecdotal (minimal verifiable data)
Caveats
Cosmetic ingredient only; not FDA-approved as a drug; no independent clinical trials; essentially no Western replication of efficacy claims.
Safety
Alternative Measures
Legal Status
US
Cosmetic ingredient only
UK
Cosmetic ingredient only
EU
Cosmetic ingredient only
AU
Cosmetic ingredient only
WADA
Not listed
Cosmetic ingredient for topical use. Not a drug.
Citations
Manufacturer/cosmetic-industry data; minimal independent peer-reviewed human evidence.